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PURPOSE. Proteomic analyses of normal and glaucomatous hu-
man optic nerve were pursued for insights into the molecular
pathology of primary open-angle glaucoma (POAG). Peptidyl
arginine deiminase 2 (PAD2), an enzyme that converts protein
arginine to citrulline, was found only in POAG optic nerve and
was probed further for a mechanistic role in glaucoma.
METHODS. Protein identification used liquid chromatography-
tandem mass spectrometry. Northern, Western, and immuno-
histochemical analyses measured PAD2 expression and/or pro-
tein citrullination and arginyl methylation in human and mouse
optic nerve and in astrocyte cultures before and after pressure
treatment. Proteins were identified after anticitrulline immu-
noprecipitation. In vitro translation of PAD2 was monitored in
polyA RNA depleted optic nerve extracts. PAD2 shRNA trans-
fections were evaluated in pressure-treated astrocytes.
RESULTS. Western and immunohistochemical analyses con-
firmed elevated PAD2 and citrullination in POAG optic nerve
and decreased arginyl methylation. PAD2 was also detected in
optic nerve from older, glaucomatous DBA/2J mice, but not in
younger DBA/2J or control C57BL6J mice. Myelin basic protein
was identified as a major citrullinated protein in POAG optic
nerve. Pressure-treated astrocytes exhibited elevated PAD2 and
citrullination without apparent change in PAD2 mRNA. Addi-
tion of exogenous polyA RNA to depleted optic nerve extracts
yielded increased PAD2 expression in POAG but not in control
extracts. Transfection with shRNA restored PAD2 and citrulli-
nation to control levels in pressure-treated astrocytes.
CONCLUSIONS. Current results support translational modulation
of PAD2 expression and a possible role for the enzyme in
POAG optic nerve damage through citrullination and structural
disruption of myelination. (Invest Ophthalmol Vis Sci. 2006;
47:2508–2514) DOI:10.1167/iovs.05-1499
Glaucoma is a group of poorly understood neurodegenera-tive disorders characterized by deformation of the optic
nerve head, loss of retinal ganglion cells, and irreversible vision
loss in approximately 70 million people worldwide.1 The risk
of glaucoma increases with age, with the disease being 5 to 10
times more prevalent at age 80 than at age 40.2 Glaucomas are
classified as primary when they occur with no known etiology,
or as secondary, where a previous illness or injury is contrib-
utory. In primary open-angle glaucoma (POAG) most but not
all patients exhibit elevated intraocular pressure (IOP) which
leads to optic nerve damage, often termed glaucomatous optic
neuropathy.3
Recent findings suggest that analysis of protein composi-
tional differences between POAG and normal ocular tissues
may provide insights into POAG’s pathologic mechanisms. For
example, in vivo expression of myocilin in optic nerve is
reduced in glaucoma as well as under conditions of elevated
IOP.3,4 Elevated pressure on cultured cells from the optic
nerve head also modulates expression of several proteins in-
cluding nitric oxide synthase-2,5 elastin,6 cytochrome
P4501B1,7 NCAM-180,8 and Hsp27.9 Other in vitro protein
expression differences in pressure-treated versus untreated as-
trocytes have recently been reported in microarray analyses.10
Previous proteomic studies in our laboratory have shown that
cochlin is overexpressed in glaucomatous trabecular mesh-
work and is possibly involved in POAG by impairing aqueous
humor circulation and elevating IOP.11 Here, we have pursued
proteomic analyses of optic nerve and report increased levels
of peptidyl arginine deiminase 2 (protein deiminase 2 or PAD2)
in POAG optic nerve. PAD2 enzyme activity is modulated by
calcium and converts protein arginine to citrulline.12 We also
found that POAG optic nerve exhibits increased citrullination
and identified several citrullinated optic nerve proteins, includ-
ing myelin basic protein. Concomitant with increased citrulli-
nation in POAG optic nerve, we observed decreased protein
arginyl methylation, suggesting that structural disruption of
myelination may contribute to optic nerve degeneration in
POAG. The present study also provides in vitro evidence of
pressure-induced translational control of PAD2 expression,




Donor eyes from normal (control) and cadaveric POAG eyes were
enucleated within 6 hours of death and obtained from the National
Disease Research Interchange and the Cleveland Eye Bank. Glaucoma-
tous eyes that had recorded optic neuropathy and progressive deteri-
oration in visual acuity together with lack of other major central
nervous system (CNS) disorders were procured. Acceptable eyes were
those that had detailed medical and ophthalmic histories. Controls eyes
were from normal donors with no optic neuropathy and no history of
eye disease or other major CNS disorders. Twelve glaucomatous and 12
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age-matched (4 years) normal eyes, all from white donors between
55 and 87 years of age were used in this study (brief clinical histories
of the optic nerve tissue donors are presented in Supplementary Table S1;
all Supplementary Material is available online at http://www.iovs.org/cgi/
content/full/47/6/2508/DC1). Two additional eyes from different 7-year-
old white male donors were used for astrocyte cell culture preparation.
Research was conducted according to the tenets of the Declaration of
Helsinki. Use of mice followed procedures in compliance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research.




Detailed methods are provided in Supplementary Materials and Meth-
ods, available online. Briefly, for proteomic analyses, proteins were
extracted from optic nerve tissue, as reported previously, but with
minor modifications.13 The proteins were identified by liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS) and bioinformatics
methods.11 Western blot analysis was performed on polyvinylidene
difluoride (PVDF) membranes according to established protocols,11,13
and primary antibodies to PAD2, myelin basic protein (MBP), myelin
proteolipid protein (PLP), myelin-associated glycoprotein (MAG), glial
fibrillary acidic protein (GFAP), citrulline, and methyl arginine. Immu-
nohistochemical analyses to localize PAD2 and citrulline in optic nerve
tissue used cadaveric eyes enucleated within 6 hours of death and fixed
immediately with calcium acetate buffered 4% para-formaldehyde.
Immunoprecipitation was performed using antibodies to citrulline and
MBP covalently coupled to protein A Sepharose beads with dimeth-
ylpimelimidate. Protein methylation assays were performed by measur-
ing incorporation of S adenosyl-L-methyl-14C methionine into ovalbu-
min using standard protocols.
RNA Isolation and Quantitation
RNA isolation was performed (TRIzol) with suitable modification of
standard protocols (see Supplementary Materials and Methods online).
Northern analyses were probed with 32P-CTP labeled PCR products
and, after a 1-hour exposure to a phosphorescence imager (Phospho-
rimager; GE Healthcare, Piscataway, NJ) screen, was imaged with a
variable-mode imager (Typhoon 8600; with Imagequant software; GE
Healthcare). Probes for PAD2 (5-aaacctggaggtcagtcccc-3 and 5-
aaacctggaggtcagtcccc-3), glyceraldehyde-3-phosphate dehydrogenase
(GPDH) (5-cttcaccaccatggagaaggc-3 and 5-ggcatggactgtggtcatgag-3),
and hypoxanthine guanine ribosyl transferase (HGRT) (5-gaagagctact-
gtaatgatcagtc-3 and 5-aaagtctggcctgtatccaacac-3) were generated by
PCR for 30 cycles with the indicated primer pairs, 32P-CTP (9.25
MBq/25 L), and recommended protocols.14
Primary Astrocyte Cultures and
Pressure Treatment
Astrocytes from Sprague-Dawley rat (Harlan, Indianapolis, IN) brain
cortex were used. Mixed glial cell suspensions were prepared from the
third postnatal day (P3) rat brain cortex region according to published
procedures,15 and GFAP-positive cells were obtained by immunopan-
ning16 (see Supplementary Materials and Methods online).
Probing Translation with Polyadenylated RNA
Depleted Extracts
Assays were performed probing translation of PAD2 on addition of
total polyA RNA to optic nerve extracts depleted of mRNAs, PAD2, and
GPDH. Extracts were first depleted of polyA RNA with oligo dT-
cellulose matrix (BioWorld, Dublin, OH) then depleted of PAD2 and
GPDH using mAb and pAb to PAD2 and GPDH, respectively, conju-
gated to protein A Sepharose beads. Approximately 100 g total
protein obtained from each donor was used for each analysis. Approx-
imately 0.15 g total polyA RNA (pooled from two nerves from white
males, aged 79 and 70 years) was added to polyA RNA depleted tissue
extracts (per 100 g of extract) and incubated at 37°C for 90 to 120
minutes. 35S labeled methionine (540 Ci/mmol; MP Biomedical Inc,
CA) was used to detect the translated product. Two identical gels
(SDS-PAGE), one with 35S-labeled and the other with cold methionine
was subjected to simultaneous side-by-side electrophoresis. The cold
methionine gel was blotted to PVDF membrane (Sigma-Aldrich Chem-
ical Co., St. Louis, MO) and probed with PAD2 and GPDH antibodies to
determine the identity of the protein bands. Detection was performed
with IR-700 or IR-800 dye-coupled secondary antibodies.12 The radio-
active protein bands corresponding to antibody detected counterparts
in cold methionine gels were excised and quantified in a scintillation
counter (1900CA Tri-Carb; Perkin Elmer, Meriden, CT).
The shRNA Treatment of Primary Astrocytes
For treatment of rat cortex astrocytes, shRNA against PAD2 (RHS1764-
9219528) was procured (pShag Magic Ver. 2.0 vector; Open Biosystems,
Huntsville, AL). This shRNA contains the sequence (5-TGCTGTTGA-
CAGTGAGCGACAGCCTTGACTCATTTGGAAATAGTGAAGCCACAGA-
TGTATTTCCAAATGAGTCAAGGCTGGTGCCTACTGCCTCGGA-3) from
the coding region of PAD2. For a negative control, we used a nonsi-
lencing shRNA sequence cloned into RHS1703 (pShag Magic 2.0; Open
Biosystems), verified to contain no homology to known mammalian
genes. Approximately 30% confluent cells (3000 primary astro-
cytes)17 were transfected (SuperFect; Qiagen, Valencia, CA) transfec-
tion reagent, purified vector (5 g) DNA (Qiagen), and the manufac-
turer’s recommended protocols. The posttransfected astrocytes were
selected on geneticin (10 g/L). The primary astrocytes were sub-
jected to pressure (40 mm of Hg) and transfected with shRNA on plates
immediately after they were brought to normal atmospheric pressure.
RESULTS
Detection of Peptidyl Arginine Deiminase 2 in
Glaucomatous Optic Nerve
Protein extracts from eight POAG and eight control optic nerve
donor tissues were separated on SDS-PAGE, gel slices were
excised from the top to the bottom of the gel (Fig. 1A) and
proteins were identified using well-established mass spectro-
metric and bioinformatics methods.13 Two additional donor
tissues not shown in Figure 1A (white females, POAG and
control, aged 72 and 73 years) were also subjected to pro-
teomic analyses. Overall, 250 proteins were identified, of
which 68 were detected only in glaucomatous optic nerve (see
Supplementary Table S2 online). Apparent proteome differ-
ences must be verified because the lack of detection by LC-
MS/MS does not necessarily mean the absence of protein ex-
pression. Notably, PAD2 was detected in four of eight
glaucomatous optic nerves by mass spectrometry (see Supple-
mentary Table S2 online), and subsequent immunoblot analysis
verified its presence in seven of seven glaucomatous tissue but
did not detect it in any normal optic nerve tissue (Fig. 1B).
Western analyses of five additional glaucomatous tissues also
detected PAD2. Overall, we found PAD2 to be uniquely asso-
ciated with 12 of 12 POAG donor optic nerves by proteomic
and Western analyses combined but in none of 12 normal
controls devoid of other neurodegenerative disorders. How-
ever, by immunoblot we detected PAD2 in optic nerve from
two of seven human donors exhibiting other CNS disorders
but without glaucoma (data not shown), a finding consistent
with reports of increased PAD2 in several neurodegenerative
diseases.18,19
Based on these findings from human optic nerve, we
probed PAD2 expression in an established animal model of
glaucoma, the DBA/2J mouse. This mouse line exhibits in-
creased IOP at approximately 6 to 8 months of age, with
progressive damage to the optic nerve and hearing loss.20
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Western analyses detected PAD2 and citrullination in the optic
nerve of 8- to 12-month-old DBA/2J mice, but not in DBA/2J
mice at 5 months of age, nor in 5- to 12-month-old control
C57BL6J mice, which do not exhibit increased IOP (Fig. 2).
Increased Citrullination and Decreased
Methylation in Glaucomatous Optic Nerve
Western analyses of POAG optic nerve showed increased
PAD2, increased citrullination but decreased protein arginyl
methylation relative to the normal control (Figs. 1B–D). De-
creased arginyl methylation (Fig. 1D) concomitant with in-
creased citrullination (Fig. 1C) is consistent with the conver-
sion of arginine to citrulline before methylation (Fig. 1B).
However, to determine whether the decreased levels of meth-
ylated proteins in POAG optic nerve could be due to down-
regulation of protein methylation activities, we performed
Western analyses for both protein arginine N-methyltransferase
1 (PRMT1) and coactivator-associated arginine methyltrans-
ferase 1 (CARM1). Normalized to GPDH, the expression levels
of CARM1 and PRMT1 appear to be comparable in control and
POAG optic nerve (see Supplementary Fig. S1 online). We also
assayed methyltransferase activity in S-AdoMet-depleted crude
tissue extracts, by using radiolabeled S-AdoMet and found es-
sentially identical activities (40,075  1,515 and 40,615 
2,061 cpm, respectively) in control and glaucomatous optic
nerve tissue (three independent experiments). Decreased
methylation could also be due to demethylimination of meth-
ylated protein arginines, and this possibility cannot be ruled
out. In any event, the observed citrullination is due to in-
creased deiminase activity, and the decreased level of methyl-
ated arginine is not due to lack of protein methyltransferase
(see Supplementary Fig. S1 online).
Immunohistochemical Localization of PAD2 and
Citrullinated Proteins
Immunohistochemical analyses showed localization of PAD2 in
the lamina cribrosa region of POAG optic nerve (Figs. 3A, 3C)
along with citrullinated proteins (Figs. 3B, 3D). The lamina
cribrosa region of the optic nerve is shown schematically in
Supplementary Figure S2 online. Identically treated control and
glaucomatous optic nerve showed clear differences in citrulli-
nated protein content in the lamina cribrosa region (Figs. 3B,
3D). Normal control optic nerve exhibited much less immuno-
histochemical reactivity for citrullinated proteins.
Identification of Citrullinated Proteins in POAG
Optic Nerve
Proteins in POAG optic nerve were immunoprecipitated with
anticitrulline antibody for protein identification (Figs. 4A, 4B).
The most intense citrulline immunoreactive component in
these immunoprecipitations (IPs) was identified by mass spec-
trometric and Western blot analysis as MBP, suggesting that
this is a major citrullinated protein in POAG optic nerve (Figs.
4C, 4D). To confirm this finding, anti-MBP was also used to
immunoprecipitate proteins from normal and POAG optic
nerve and subsequently probed with anticitrulline antibody.
More citrullinated MBP was observed in POAG than in normal
optic nerve extracts (Fig. 4). Mass spectrometric and Western
analyses of anticitrulline immunoprecipitation products also
detected citrullinated myelin proteolipid protein and myelin
associated glycoprotein in POAG optic nerve (Fig. 4D). Mass
spectrometry also detected myelin P0 protein and myelin oli-
godendrocyte protein in the anticitrulline IP. Other proteins
FIGURE 2. Western blot analysis using PAD2 and citrulline antibodies.
(A) Anti-PAD2 Western analyses of control (C57BL6J) and DBA/2J mice
optic nerve at indicated ages (in months). (B) Anti-citrulline Western
analyses of mouse optic nerve.
FIGURE 1. Elevated PAD2 levels and citrullination in glaucomatous
optic nerve. (A) Representative SDS-PAGE of human optic nerve pro-
tein (10 g per lane) from POAG and control donors (Coomassie
blue staining). Gel slices were excised and proteins identified by LC
MS/MS (see Supplementary Table S2 online). (B) Representative West-
ern analyses with monoclonal anti-PAD2 of protein extracts from
human optic nerve demonstrating the presence of 72-kDa protein
uniquely in glaucomatous tissues. (C) Western analyses with rabbit
polyclonal antibody to citrulline (10 g protein per lane). Before
applying antibody, membrane immobilized protein was treated with
2,3-butanedione monooxime and antipyrine in a strong acid atmo-
sphere enabling chemical modification of citrulline into ureido groups
and ensures detection of citrulline-containing proteins regardless of
neighboring amino acid sequences. (D) Western analyses with mouse
monoclonal antibody to protein methylarginine (10 g protein per
lane). Protein was extracted from the optic nerve of white cadaveric
donor eyes; age and gender are indicated.
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identified in the anticitrulline IP are listed in Supplementary
Table S3 online.
Pressure and PAD2 Expression In Vivo and
In Vitro
Apparent high levels of PAD2 were observed in donors with
elevated IOP (Fig. 5A). Optic nerve from a 76-year-old female
POAG donor with high IOP but no surgical or pharmacological
intervention, and without head or eye injury from a fatal
automobile accident, was found to exhibit a very high level of
PAD2. Other donor eyes that had undergone either surgical or
combined surgical and pharmacological intervention to relieve
elevated IOP were also analyzed for PAD2. Notably, we ob-
served that POAG optic nerve PAD2 remained detectable after
surgical or pharmacological intervention and after the IOP
returned to normal. Results from two such glaucomatous do-
nors (86M and 85M) subjected to trabeculectomy with the 85M
donor also receiving verapamil (a calcium modulator) are pre-
FIGURE 3. Immunohistochemical localization of PAD2 and citrulli-
nated proteins in the optic nerve. Control (82-year-old male) and
glaucomatous (84-year-old male) optic nerve scanning confocal micro-
scopic images are shown for the white tissue donors. (A, C) Anti-PAD2
staining (secondary conjugated with AlexaFluor 594) images; PAD2
immunoreactivity was predominantly observed in glaucomatous optic
nerve. (B, D) Control and glaucomatous optic nerve images stained
with anti-citrulline antibodies (secondary conjugated with AlexaFluor
488). Citrulline immunoreactivity was predominantly observed in glau-
comatous optic nerve.
FIGURE 4. Immunoprecipitation of hu-
man optic nerve proteins. (A) Coomas-
sie blue detection of immunoprecipita-
tion (IP) products from glaucomatous
(G) and normal (N) optic nerve pro-
teins with anti-citrulline or anti-MBP
and of glaucomatous and normal optic
nerve extracts without IP (15 g). (B)
Western detection with anti-citrulline
of anti-citrulline or anti-MBP IP prod-
ucts from glaucomatous and normal op-
tic nerve extracts. (C) Western detec-
tion with anti-MBP of anti-citrulline or
anti-MBP IP products from glaucoma-
tous and normal optic nerve extracts.
(D) Western detection with antibodies
to myelin proteolipid protein (PLP),
myelin-associated glycoprotein (MAG),
and MBP of anti-citrulline IP products
from glaucomatous optic nerve.
FIGURE 5. Elevated level of PAD2 and citrulline in response to pres-
sure. (A) Representative Western analyses with anti-PAD2 and anti-
GPDH of human optic nerve demonstrating the presence of PAD2
relative to GPDH control immunoreactivity. Protein extracted from the
optic nerve of cadaveric white donor eyes of the indicate age and
gender. All glaucomatous donors had elevated IOP and were subjected
to surgical intervention except 76F. 85M also received verapamil, a
calcium modulator. (B) Representative Western analyses with anti-
PAD2 of rat brain astrocytes subjected to 40 mm Hg pressure for 5
hours and then returned to atmospheric pressure for up to 4 days, as
indicated. (C) Representative Western blot analysis with anti-citrulline
of protein extracts (5 g) from astrocytes subjected to elevated pres-
sure as in (B). (D) Representative Northern analyses of total RNA (2
g) isolated from pressure-treated or untreated astrocytes as in (B).
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sented in Figure 5A. Although both (86M and 85M) show lower
levels of optic nerve PAD2 compared with those without
intervention (76F), their PAD2 level is still high compared with
normal controls. In the verapamil-treated eye (85M), the PAD2
level appeared lower than in the other POAG eyes, with or
without intervention (86M and 76F).
To explore in vitro whether pressure induces PAD2 and
subsequent citrullination, primary rat cortex astrocyte cultures
were subjected to an increase in pressure by 40 mm Hg for 5
hours and then restored to atmospheric pressure. The short-
term elevated pressure led to increased PAD2 in astrocytes that
was still detectable after 4 days at atmospheric pressure by
Western blot analysis (Fig. 5B) and immunohistochemistry (see
Supplementary Fig. S3 online). Increased citrullination was also
observed in the astrocytes concomitant with pressure treat-
ment and remained detectable after 4 days at atmospheric
pressure (see Supplementary Fig. S3C online). In contrast to
pressure-induced changes in PAD2 protein expression, by
Northern blot analysis PAD2 mRNA levels did not significantly
change in astrocytes subjected to pressure (Fig. 5D). These
observations were replicated in astrocytes derived from a
7-year-old human optic nerve head (data not shown).
Translational Control of PAD2 Overexpression
To further probe whether increased PAD2 expression in vivo is
due to increased PAD2 mRNA, total RNA from normal human
and POAG optic nerve were subjected to Northern blot anal-
ysis. The amount of the PAD2 transcript normalized to that of
GPDH was found to be very similar between seven control and
seven glaucomatous donors (Fig. 6A), suggesting PAD2 over-
expression in POAG optic nerve may be translationally regu-
lated. Additional experiments supporting translational control
of PAD2 expression were performed with normal and POAG
optic nerve extracts depleted of both polyadenylated RNA and
the PAD2 and GPDH proteins (Fig. 6B, 6C). These depleted
extracts lack translation capability without exogenous mRNA.
On addition of exogenous polyadenylated RNA to the depleted
extracts, a large increase in PAD2 expression (relative to
GPDH) was observed in the POAG extracts but not in the
control extracts (Fig. 6B, 6C).
Downregulation of Citrullination with
PAD2 shRNA
Increased PAD2 and citrullination were observed in astrocytes
subjected to pressure even after restoration of atmospheric
pressure (Fig. 5). As a possible approach to reducing pressure-
induced citrullination, we tested the effect of lowering PAD2
mRNA in vitro in astrocytes. Primary culture astrocytes were
subjected to pressure and transfected with shRNA immediately
after they were brought to atmospheric pressure. We found
that astrocytes treated with a PAD2 specific shRNA (but not
with a nonspecific shRNA) exhibited reduced PAD2 expres-
sion (Fig. 7A) and reduced citrullination (Fig. 7B) as a conse-
quence of degradation of the mRNA transcript (Fig. 7C). Al-
though some residual citrullination was observed, PAD2 mRNA
was completely removed by shRNA within the sensitivity of
detection (Fig. 7C). We did not observe any difference in cell
morphology due to this reduction in mRNA, although immu-
nohistochemical analysis showed that PAD2 was reduced in
astrocytes treated with shRNA (see Supplementary Figs. S4B,
S4C online) compared with pressure-treated group without
shRNA (see Supplementary Figs. S3B, S3C online).
DISCUSSION
Classic proteomic methods initially detected PAD2 in the optic
nerve of glaucomatous but not normal human donors. Subse-
quently, PAD2 was found to be uniquely associated with glau-
comatous human optic nerve by Western and immunohisto-
chemical analyses of additional POAG and normal donor
tissues. Western blot analysis also demonstrated the presence
FIGURE 6. Translational modulation
of PAD2. (A) Representative North-
ern analyses of total RNA (5 g) iso-
lated from normal control and glau-
comatous human optic nerve. Donor
age and gender are indicated. (B) In
vitro translation of PAD2 (measured
as dissociations per minute) was
monitored in polyA RNA, PAD2, and
GPDH depleted normal control and
glaucomatous optic nerve extracts.
Radioactive PAD2 (relative to GPDH)
is shown. (C) Parallel Western blot
analysis of in vitro translation prod-
ucts in (B) using anti-PAD2 and anti-
GPDH with 700-IR coupled second-
ary antibodies. Gray-scale images are
from infrared scanning. Donor age
and gender are indicated.
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of PAD2 in optic nerve from the DBA/2J glaucomatous mouse
at ages 8 to 12 months, but not in younger DBA/2J mice that do
not exhibit elevated IOP nor in optic nerve from control
C57BL6J mice. Proteomic analyses identified many other pro-
teins in human optic nerve (see Supplementary Table S2 on-
line); however, the significance of other proteins detected only
in glaucomatous optic nerve remains to be determined.
PAD2 converts arginine to citrulline, and we observed in-
creased protein citrullination and decreased protein arginyl
methylation in POAG optic nerve. Recently, PAD2, directed
citrullination was associated with kainite-induced neurodegen-
eration in rat brain.18,19 PAD2 predominantly occurs in neuro-
nal tissues21; however, five protein deiminases have been iden-
tified in a variety of tissues, including protein deiminase-1, -2,
-3, and -6 which are cytosolic and protein deiminase 4 which
exhibits nuclear localization.22 PAD4 was recently found to
catalyze reverse methylation or demethylination as well as
deimination of proteins.23,24 PADs have been implicated in
demyelinating diseases,21 and citrullination has been impli-
cated in diseases such as autoimmune rheumatoid arthritis,25
multiple sclerosis,21 and amyotrophic lateral sclerosis.26
The consequences of citrullination are many and varied.
Notably, myelin contains several arginine-rich proteins that are
susceptible to citrullination,27 including MBP which we de-
tected as a major citrullinated protein in POAG optic nerve.
MBP is one of the most abundant proteins of the myelin sheath
and functions in maintaining the stability of the sheath.28
Citrullinated MBP exhibits altered properties relative to the
unmodified protein, including a lower net positive charge,
which disrupts its tertiary structure and ability to interact with
lipids and maintain a compact myelin sheath.29,30 Citrullination
also decreases the ability of MBP to aggregate large unilamellar
vesicles (LUVs),29 a process essential for adhesion between
intracellular surfaces of myelin. Citrullinated MBP exhibits in-
creased susceptibility to cathepsin D proteolysis, which may
generate immunodominant peptides leading to sensitization
of T-cells for the autoimmune response in demyelinating dis-
eases.30 Citrullination also appears to inhibit cell proliferation,
leading to cell cycle arrest and apoptosis.31,32 Such mecha-
nisms may all play a role in glaucomatous neuropathy. The
presence of multiple citrullinated proteins in POAG optic
nerve, including MBP, myelin proteolipid protein, and myelin-
associated glycoprotein among others, would appear likely to
disrupt myelination. Citrullination of optic nerve head matrix
proteins may weaken their anchorage and overall weakness at
the level of optic nerve head. We hypothesize that citrullina-
tion causes changes in the dynamics of myelin components
and also may cause disruption of the optic nerve head matrix
protein framework that may initiate or contribute to glauco-
matous neuropathy.
A variety of factors trigger PAD2 expression. Calcium im-
balance has been implicated in eliciting PAD2 activity,19 and
perhaps calcium influences the increased PAD2 observed in
myelinating immature oligodendrocytes.33 Increased IOP in
glaucoma often is associated with influx of calcium (e.g., from
ischemia), resulting in increased intracellular calcium.34 Nota-
bly in myelin, calcium concentration plays an important role in
modulating several protein interactions,28,35 including for ex-
ample MBP interaction with calmodulin, which citrullination
can disrupt.36 In POAG, events triggered by intraocular pres-
sure, including fluctuations in optic nerve intracellular calcium
concentration, may increase the level of PAD2 and citrullina-
tion. Indeed, our in vivo results from POAG donors (Fig. 5A)
and the DBA/2J glaucomatous mouse model (Fig. 2) support
elevated IOP as a possible contributing factor to PAD2 expres-
sion. Our in vitro results (Fig. 5B) also suggest that pressure
induces PAD2 expression in astrocytes; however, competing
factors in the pressure treated astrocyte model may contribute
to the observed results. Others have shown in astrocytes that
hypoxia induces PAD2 expression, citrullination, and elevated
intracellular calcium concentration.34,37 Accordingly, fluctua-
tions in gas composition during the 5-hour astrocyte pressure
treatment used in the present study may have altered O2 and
CO2 concentrations, resulting in hypoxia and/or media pH
changes that impacted PAD2 expression.
Our observations are consistent with posttranscriptional
control of PAD2 expression. In a preliminary analysis, optic
nerve– derived RNA (pooled from two donors each: control
and glaucomatous) used in a microarray analysis revealed
changes in mRNA levels for 1923 proteins between control
and glaucomatous optic nerve tissue; however, PAD2 was
not among them. (Supporting microarray data have been
deposited in the National Center for Biotechnology’s GEO
database, accession number GSE2387.) Optic nerve PAD2
mRNA levels appeared to be very similar between control
and glaucomatous donors in vivo (Fig. 6A) and between
pressure-treated and untreated astrocytes in vitro (Fig. 5D).
However, glaucomatous optic nerve extracts depleted of
polyadenylated RNA, PAD2 and GPDH, exhibited a signifi-
cant increase in PAD2 expression (relative to GPDH) on
addition of equal amounts of polyadenylated RNA, with no
comparable increase in control extracts (Fig. 6B, 6C). These
in vitro data suggest that the overexpression of PAD2 in
glaucomatous tissue is primarily controlled at the transla-
tional level. However, in vivo, a lower normal steady state
expression level could result from an increased degradation
rate as well as from a decrease in the rate of translation. We
have shown that in vitro targeted degradation of PAD2
mRNA with shRNA in pressure-treated astrocytes leads to a
decrease in PAD2 and citrullination. The therapeutic poten-
tial of such targeted approaches remains to be evaluated in
appropriate animal models of glaucoma. Whether PAD2 ex-
pression and citrullination cause neurodegeneration in
POAG or are consequential to damage in glaucomatous optic
nerve also remains to be determined. In any event, the
present results implicate optic nerve PAD2-directed citrulli-
nation in the pathogenesis of glaucoma.
FIGURE 7. Transfection with shRNA restored PAD2 and citrullination
to control levels in pressure-treated astrocytes. Astrocytes were sub-
jected to 40 mm Hg then transfected with PAD2 shRNA and analyzed
for PAD2 expression and citrullination. The control is a nonsilencing
shRNA sequence. (A) Anti-PAD2 Western blot analysis; (B) anti-citrul-
line Western blot analysis; (C) Northern blot analysis of total RNA for
PAD2 mRNA.
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